EDAP TMS S.A.
Parc d'Activités la Poudrette-Lamartine
4/6, rue du Dauphiné
Vaulx-en-Velin
69120
France
Tel: 33-4-72-15-31-50
Fax: 33-4-72-15-31-51
Website: http://www.edap-tms.com/
348 articles about EDAP TMS S.A.
-
EDAP to Announce Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024
3/13/2024
EDAP TMS SA, the global leader in robotic energy-based therapies, announced that it will release its financial results for the fourth quarter and full-year ended December 31, 2023, before the markets open on Wednesday, March 27th, 2024.
-
EDAP Announces FDA Breakthrough Device Designation for Focal One® in the Treatment of Deep Infiltrating Rectal Endometriosis
3/4/2024
EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced today that its Focal One platform has been granted Breakthrough Device designation by the US Food and Drug Administration (FDA) for the treatment of deep infiltrating endometriosis (DIE).
-
EDAP Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One HIFU Therapy for the Treatment of Deep Infiltrating Rectal Endometriosis
2/1/2024
EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced today that it has completed enrollment in its Phase 3 study (Endo-HIFU-R2) evaluating Focal One High-Intensity Focused Ultrasound (HIFU) therapy for the treatment of deep infiltrating rectal endometriosis.
-
EDAP Announces Preliminary Fourth Quarter Record Focal One® System Sales and Placements
1/8/2024
EDAP TMS SA, the global leader in robotic energy-based therapies, announced preliminary Focal One placement results for the fourth quarter of calendar year 2023.
-
EDAP Announces Positive Opinion for Reimbursement from the French National Authority for Health (HAS) for HIFU treatment of Prostate Cancer
12/12/2023
EDAP TMS SA (Nasdaq: EDAP), (“EDAP”), the global leader in robotic energy-based therapies, today announced that the French National Authority for Health (“HAS”) released a favorable recommendation for the reimbursement of high-intensity focused ultrasound (HIFU) therapy in the treatment of prostate cancer.
-
EDAP Appoints Lance Willsey, M.S., M.D. to Board of Directors
12/6/2023
EDAP TMS SA, the global leader in robotic energy-based therapies, announced the appointment of Lance Willsey, M.S., M.D. to its Board of Directors.
-
EDAP Receives 2023 Industry Category Award from the French National Institute for Intellectual Property (INPI) for Its Therapeutic Ultrasound Technology
11/30/2023
EDAP TMS SA, the global leader in robotic energy-based therapies, announced that is has received the Industry Category Award from the French National Institute for Intellectual Property based on the Company’s innovative therapeutic ultrasound technology.
-
EDAP Announces Third Quarter 2023 Financial Results
11/9/2023
EDAP TMS SA, the global leader in robotic energy-based therapies, reported unaudited financial results for the third quarter ending September 30, 2023.
-
EDAP Announces Second Quarter 2023 Financial Results
8/24/2023
EDAP TMS SA, the global leader in robotic energy-based therapies, reported unaudited financial results for the second quarter ending June 30, 2023, and announced the appointment of Ryan Rhodes to the Board of Directors of the Company.
-
EDAP Announces Reimbursement Approval in Switzerland for the Use of High-Intensity Focused Ultrasound (HIFU) in the Treatment of Prostate Cancer
7/26/2023
EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it has received reimbursement approval in Switzerland for the use of High-Intensity Focused Ultrasound (HIFU) in the treatment of prostate cancer.
-
EDAP to Present at the 2023 Jefferies Healthcare Conference
5/24/2023
EDAP TMS SA, the global leader in robotic energy-based therapies, announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a presentation and host 1x1 investor meetings at the Jefferies Healthcare Conference, which is being held June 7-9, 2023, in New York City.
-
EDAP Announces First Quarter 2023 Financial Results
5/17/2023
EDAP TMS SA, the global leader in robotic energy-based therapies, announced unaudited financial results for the first quarter ended March 31, 2023.
-
EDAP Announces Major Presence at Upcoming Annual Meeting of the American Urological Association (AUA)
4/21/2023
EDAP TMS SA (Nasdaq: EDAP) (“the Company”) today announced that the Company will be showcasing its Focal One® Robotic High Intensity Focused Ultrasound (HIFU) platform at the upcoming Annual Meeting of the American Urological Association (AUA), the largest gathering of urologists worldwide, which will be held April 28th through May 1st in Chicago, IL.
-
EDAP Announces Regulatory Clearance of ExactVu Micro-Ultrasound in Japan
4/6/2023
EDAP TMS SA (Nasdaq: EDAP) (“the Company”), a global leader in robotic energy-based therapies, today provided a regulatory and clinical update.
-
EDAP Reports Record Fourth Quarter and Full-Year 2022 Results and Announces Leadership Succession Plan to Develop Global Group Strategy
3/30/2023
EDAP TMS SA, a global leader in robotic energy-based therapies, announced unaudited financial results for the fourth quarter and full-year 2022 and announced a change in its leadership, effective May 1, 2023.
-
EDAP Presents Positive Results from Non-Inferiority Study Comparing Outcomes of Focal One HIFU Versus Radical Prostatectomy at EAU23
3/21/2023
EDAP TMS SA (Nasdaq: EDAP) (“the Company”) today announced a recent presentation of positive results from a large, multicenter, non-inferiority study comparing Focal One high intensity focused ultrasound (HIFU) versus radical prostatectomy (RP) at the 38th Annual Congress of the European Association of Urology (EAU), which was held March 10-13, in Milan, Italy.
-
EDAP to Announce Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 30th
3/9/2023
EDAP TMS SA announced that it will release its financial results for the fourth quarter and full-year ended December 31, 2022, before the markets open on Thursday, March 30th, 2023.
-
EDAP Announces Record Preliminary Fourth Quarter and Full-Year 2022 Revenue
2/14/2023
EDAP TMS SA, a global leader in robotic energy-based therapies, announced preliminary unaudited fourth quarter and full year 2022 revenue and other financial highlights.
-
EDAP Announces Positive Results from Phase 2 Study Evaluating Therapeutic High-Intensity Focused Ultrasound (HIFU) for the Treatment of Rectal Endometriosis
1/31/2023
EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced positive clinical results from the Endo-HIFU-R1 Phase 2 study evaluating the safety of therapeutic high-Intensity focused ultrasound (HIFU) for the treatment of rectal endometriosis.
-
EDAP Appoints Medical Capital Equipment Finance Veteran Ken Mobeck as Chief Financial Officer of Company’s U.S. Subsidiary
12/6/2022
EDAP TMS SA, the global leader in robotic energy-based therapies, announced that the Company has hired medical capital equipment finance industry veteran Ken Mobeck as Chief Financial Officer of EDAP Technomed Inc., the Company’s U.S. subsidiary.